Low Leverage / Stronger CapitalizationExtremely low leverage and increased equity provide durable financial flexibility. With minimal debt, the company can absorb ongoing R&D and pilot costs, extend runway for commercialization, and negotiate partnerships without immediate refinancing pressure—supporting multi‑quarter scale-up efforts.
Validation Pathway Via Large Partner TrialsSecuring trials with major shipping players offers a structural route to commercial offtake and market entry. Successful MSC/Cargill validation creates repeatable demand channels for MSAR/bioMSAR, enabling transition from trials to long‑term supply contracts and licensing revenue streams.
Strengthened Technical & Commercial TeamAdding senior refinery and industry-experienced hires raises the company’s ability to engage refineries and commercial partners, accelerate scale-up planning, and de‑risk technical-commercial handoffs. Bolstered expertise improves chances of converting pilots into plant commissions.